

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
April 01, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

APRIL 01 2005

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b):82-\_\_\_\_\_

TREASURY STOCK

STATUS RE NOVO NORDISK'S HOLDING OF ITS OWN SHARES (31 MARCH 2005)

In continuation of the company's announcement on 30 April 2004 of a planned  
share repurchase programme, and pursuant to Section 29 of the Danish Securities  
Trading Act and Section 204.33 of the New York Stock Exchange Listed Company  
Manual, this is to report that as of today, Novo Nordisk A/S (NYSE: NVO) and its

## Edgar Filing: NOVO NORDISK A S - Form 6-K

wholly-owned affiliates owns 23,174,069 of its own B shares of DKK 2, corresponding to a total nominal value of DKK 46,348,138 or 6.53% of the total share capital.

In the first quarter of 2005 a total of 715,000 B shares were repurchased by Novo Nordisk A/S, and 126,060 B shares were disposed of to employees who exercised options granted by Novo Nordisk.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 20,250 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

For further information please contact:

Media:

Outside North America:

Elin K Hansen  
Tel (direct):  
(+45) 4442 3450

Investors:

Outside North America:

Mogens Thorsager Jensen  
Tel (direct):  
(+45) 4442 7945

Palle Holm Olesen

Tel (direct):

(+45) 4442 6175

In North America:

Susan T Jackson  
Tel (direct):  
(+1) 609 919 7776

In North America:

Mads Veggerby Lausten  
Tel (direct):  
(+45) 4443 7919

Stock Exchange Announcement No 14/2005

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: APRIL 01 2005

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer